Shu G Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1043423/publications.pdf

Version: 2024-02-01

88 papers	8,734 citations	53660 45 h-index	58464 82 g-index
92 all docs	92 docs citations	92 times ranked	6752 citing authors

#	Article	IF	Citations
1	Potential longâ€term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimer's and Dementia, 2022, 18, 1248-1259.	0.4	7
2	Skin Î±-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurology, 2021, 78, 30.	4.5	125
3	Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinsonâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 62.	2.4	79
4	Gutâ€“microbiotaâ€“microgliaâ€“brain interactions in Alzheimerâ€™s disease: knowledge-based, multi-dimensional characterization. Alzheimer's Research and Therapy, 2021, 13, 177.	3.0	15
5	Diagnostic value of skin RT-QuIC in Parkinsonâ€™s disease: a two-laboratory study. Npj Parkinson's Disease, 2021, 7, 99.	2.5	41
6	Vitamin B12 modulates Parkinsonâ€™s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 2019, 29, 313-329.	5.7	42
7	Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 63, 157-165.	1.2	29
8	Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls. Journal of the Neurological Sciences, 2018, 388, 203-207.	0.3	13
9	Novel strain properties distinguishing sporadic prion diseases sharing prion protein genotype and prion type. Scientific Reports, 2017, 7, 38280.	1.6	18
10	Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Scientific Reports, 2016, 6, 34477.	1.6	319
11	Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinsonâ€™s Disease. Biochemistry, 2016, 55, 4519-4532.	1.2	29
12	Prion protein functions as a ferrireductase partner for ZIP14 and DMT1. Free Radical Biology and Medicine, 2015, 84, 322-330.	1.3	67
13	Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease. Human Molecular Genetics, 2015, 24, 1322-1335.	1.4	38
14	The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin. Therapeutic Targets for Neurological Diseases, 2015, 2, .	2.2	9
15	pH-dependent kinetics of copper ions binding to amyloid-Î² peptide. Journal of Inorganic Biochemistry, 2013, 119, 21-27.	1.5	17
16	Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Human Molecular Genetics, 2013, 22, 328-344.	1.4	70
17	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Human Molecular Genetics, 2012, 21, 1931-1944.	1.4	356
18	LRRK2 Directly Interacts with DLP1 to Regulate Mitochondrial Dynamics and Function. Microscopy and Microanalysis, 2012, 18, 196-197.	0.2	0

#	Article	IF	Citations
19	Assessing Prion Infectivity of Human Urine in Sporadic Creutzfeldt-Jakob Disease. Emerging Infectious Diseases, 2012, 18, 21-28.	2.0	22
20	CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinsonâ€™s disease. Journal of Neural Transmission, 2011, 118, 23-26.	1.4	13
21	Selection and characterization of DNA aptamers against PrP^{Sc}. Experimental Biology and Medicine, 2011, 236, 466-476.	1.1	20
22	LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiology of Disease, 2010, 40, 73-81.	2.1	128
23	Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship. Cell Research, 2010, 20, 397-399.	5.7	13
24	Paradoxical Role of Prion Protein Aggregates in Redox-Iron Induced Toxicity. PLoS ONE, 2010, 5, e11420.	1.1	18
25	Characterization of the Prion Protein in Human Urine. Journal of Biological Chemistry, 2010, 285, 30489-30495.	1.6	14
26	Penicillin Sulfone Inhibitors of Class D Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2010, 54, 1414-1424.	1.4	42
27	Cryptic Peptides of the Kringle Domains Preferentially Bind to Disease-Associated Prion Protein. Journal of Alzheimer's Disease, 2009, 16, 421-431.	1.2	8
28	Neuronal mitochondrial amelioration by feeding acetylâ€Lâ€carnitine and lipoic acid to aged rats. Journal of Cellular and Molecular Medicine, 2009, 13, 320-333.	1.6	105
29	Leucineâ€rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease. Journal of Neuroscience Research, 2009, 87, 1283-1295.	1.3	109
30	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 32.	4.4	34
31	The Roc domain of leucineâ€rich repeat kinase 2 is sufficient for interaction with microtubules. Journal of Neuroscience Research, 2008, 86, 1711-1720.	1.3	155
32	Leucine-Rich Repeat Kinase 2 Colocalizes with Î±-Synuclein in Parkinsonâ€™s Disease, but Not Tau-Containing Deposits in Tauopathies. Neurodegenerative Diseases, 2008, 5, 222-224.	0.8	29
33	FadA from Fusobacterium nucleatum Utilizes both Secreted and Nonsecreted Forms for Functional Oligomerization for Attachment and Invasion of Host Cells. Journal of Biological Chemistry, 2007, 282, 25000-25009.	1.6	139
34	Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6800-6805.	3.3	35
35	The Parkinsonâ€™s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Experimental Cell Research, 2007, 313, 3658-3670.	1.2	192
36	Leucine-rich repeat kinase 2: Relevance to Parkinson's disease. International Journal of Biochemistry and Cell Biology, 2006, 38, 1469-1475.	1.2	44

#	Article	IF	Citations
37	Advances in Prion Disease Surveillance. Advances in Clinical Chemistry, 2006, 41, 263-292.	1.8	0
38	Gerstmann-StrÃussler-Scheinker. Journal of Neuropathology and Experimental Neurology, 2006, 65, 642-651.	0.9	33
39	DNA Aptamers That Bind to PrP^C and Not Prp^{Sc} Show Sequence and Structure Specificity. Experimental Biology and Medicine, 2006, 231, 204-214.	1.1	89
40	LRRK2 in Parkinson's disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2006, 1, 17.	4.4	40
41	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotoxicity Research, 2006, 10, 43-56.	1.3	76
42	LRRK2 protein is a component of lewy bodies. Annals of Neurology, 2006, 60, 617-618.	2.8	57
43	Fusion of Doppel to Octapeptide Repeat and Nâ€Terminal Half of Hydrophobic Region of Prion Protein Confers Resistance to Serum Deprivation. Microbiology and Immunology, 2006, 50, 203-209.	0.7	20
44	Chronic Wasting Disease of Elk and Deer and Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2006, 281, 4199-4206.	1.6	37
45	Sensitive Detection of Prion Protein in Human Urine. Experimental Biology and Medicine, 2005, 230, 343-349.	1.1	13
46	Chronic Wasting Disease of Elk: Transmissibility to Humans Examined by Transgenic Mouse Models. Journal of Neuroscience, 2005, 25, 7944-7949.	1.7	235
47	Creutzfeldt-Jakob Disease (CJD) with a Mutation at Codon 148 of Prion Protein Gene. American Journal of Pathology, 2005, 167, 1729-1738.	1.9	34
48	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. Journal of the Neurological Sciences, 2005, 229-230, 285-292.	0.3	55
49	Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology, 2004, 63, 436-442.	1.5	119
50	Protease-Resistant Human Prion Protein and Ferritin Are Cotransported across Caco-2 Epithelial Cells: Implications for Species Barrier in Prion Uptake from the Intestine. Journal of Neuroscience, 2004, 24, 11280-11290.	1.7	96
51	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. Neurological Research, 2004, 26, 547-553.	0.6	28
52	Antibody to DNA detects scrapie but not normal prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1380-1385.	3.3	103
53	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-Î². Biochemistry, 2004, 43, 560-568.	1.2	362
54	Characterization of Prion Proteins. , 2003, 217, 305-314.		7

#	Article	IF	Citations
55	Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clinics in Laboratory Medicine, 2003, 23, 43-64.	0.7	57
56	Sporadic and familial CJD: classification and characterisation. British Medical Bulletin, 2003, 66, 213-239.	2.7	449
57	Identification of Novel Proteinase K-resistant C-terminal Fragments of PrP in Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2003, 278, 40429-40436.	1.6	129
58	Insomnia associated with thalamic involvement in E200K Creutzfeldtâ€“Jakob disease. Neurology, 2002, 58, 362-367.	1.5	50
59	Alteration of Substrate Selectivity through Mutation of Two Arginine Residues in the Binding Site of Amadoriase II from Aspergillus sp.. Biochemistry, 2002, 41, 4453-4458.	1.2	22
60	A Journey through the Species Barrier. Neuron, 2002, 34, 854-856.	3.8	16
61	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	1.0	62
62	Mechanisms of phenotypic heterogeneity in prion, Alzheimer and other conformational diseases. Journal of Alzheimer's Disease, 2001, 3, 87-95.	1.2	6
63	Molecular profiling of paired helical filaments. Journal of Alzheimer's Disease, 2001, 3, 467-469.	1.2	0
64	Aberrant metal binding by prion protein in human prion disease. Journal of Neurochemistry, 2001, 78, 1400-1408.	2.1	178
65	Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease. Journal of Pathology, 2001, 194, 9-14.	2.1	36
66	Novel Differences between Two Human Prion Strains Revealed by Two-dimensional Gel Electrophoresis. Journal of Biological Chemistry, 2001, 276, 37284-37288.	1.6	53
67	Genetic influence on the structural variations of the abnormal prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10168-10172.	3.3	285
68	Aggregation and Fibrillization of the Recombinant Human Prion Protein huPrP90â^'231. Biochemistry, 2000, 39, 424-431.	1.2	216
69	Expression and Structural Characterization of the Recombinant Human Doppel Protein,. Biochemistry, 2000, 39, 13575-13583.	1.2	38
70	Cloning of Amadoriase I Isoenzyme fromAspergillussp.:Â Evidence of FAD Covalently Linked to Cys342â€,â€¡. Biochemistry, 2000, 39, 1515-1521.	1.2	45
71	PrPSc typing by N-terminal sequencing and mass spectrometry. , 2000, , 209-216.		7
72	Tau gene mutation in familial progressive subcortical gliosis. Nature Medicine, 1999, 5, 454-457.	15.2	189

#	Article	IF	Citations
73	Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15598-15602.	3.3	90
74	Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8322-8327.	3.3	206
75	Molecular Pathology of Fatal Familial Insomnia. Brain Pathology, 1998, 8, 539-548.	2.1	98
76	Mechanisms of Phenotypic Heterogeneity in Human Prion Diseases. , 1998, , 37-41.		0
77	Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation. Journal of Biological Chemistry, 1997, 272, 28461-28470.	1.6	86
78	Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nature Medicine, 1997, 3, 1009-1015.	15.2	88
79	Typing prion isoforms. Nature, 1997, 386, 232-233.	13.7	268
80	Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature, 1997, 388, 285-288.	13.7	259
81	Molecular basis of phenotypic variability in sporadc creudeldt-jakob disease. Annals of Neurology, 1996, 39, 767-778.	2.8	819
82	Fatal Familial Insomnia and Familial Creutzfeldtâ€Jakob Disease: Clinical, Pathological and Molecular Features. Brain Pathology, 1995, 5, 43-51.	2.1	192
83	Regional distribution of protease-resistant prion protein in fatal familial insomnia. Annals of Neurology, 1995, 38, 21-29.	2.8	165
84	Truncated Forms of the Human Prion Protein in Normal Brain and in Prion Diseases. Journal of Biological Chemistry, 1995, 270, 19173-19180.	1.6	455
85	Synergistic activation by cis-fatty acid and diacylglycerol of protein kinase C and protein phosphorylation in hippocampal slices. Neuroscience, 1995, 68, 1017-1026.	1.1	3
86	PROTEASE-RESISTANT PRION PROTEIN IN SPORADIC CREUTZFELDT-JAKOB DISEASE (CJD). Journal of Neuropathology and Experimental Neurology, 1995, 54, 416.	0.9	3
87	Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2839-2842.	3.3	308
88	Inhibition of brain protein kinase C subtypes by lead. Journal of Pharmacology and Experimental Therapeutics, 1993, 264, 757-61.	1.3	53